Thiothymidine Combined with UVA As a Potential Novel Therapy for Bladder Cancer
British Journal of Cancer (2011) 104, 1869 – 1876 & 2011 Cancer Research UK All rights reserved 0007 – 0920/11 www.bjcancer.com Thiothymidine combined with UVA as a potential novel therapy for bladder cancer SW Pridgeon1,5, R Heer1,4, GA Taylor1, DR Newell1, K O’Toole1, M Robinson2, Y-Z Xu3, P Karran3 and *,1 AV Boddy 1 2 Northern Institute for Cancer Research, Medical School, Newcastle University, Newcastle NE2 4HH, UK; Department of Histopathology, Royal Victoria 3 4 Infirmary, Newcastle, UK; Cancer Research UK London Research Institute, Clare Hall Laboratories, South Mimms, UK; Department of Urology, Freeman Hospital, Newcastle, UK 4 BACKGROUND: Thiothymidine (S TdR) can be incorporated into DNA and sensitise cells to DNA damage and cell death following 4 exposure to UVA light. Studies were performed to determine if the combination of S TdR and UVA could be an effective treatment for bladder cancer. 4 METHODS: Uptake and incorporation of S TdR was determined in rat and human bladder tumour cell lines. Measures of DNA 4 crosslinking and apoptosis were also performed. In vivo activity of the combination of S TdR and UVA was investigated in an orthotopic model of bladder cancer in rats. RESULTS: Thiothymidine (200 mM) replaced up to 0.63% of thymidine in rat and tumour bladder cancer cells. The combination of 4 À2 S TdR (10–200 mM) and UVA (1–5 kJ m ) caused apoptosis and cell death at doses that were not toxic alone. Addition of 4 raltitrexed (Astra Zeneca, Alderley Edge, Cheshire, UK) increased the incorporation of S TdR into DNA (up to 20-fold at IC5) and further sensitised cells to UVA.
[Show full text]